title: Regulatory watch: Impact of scientific advice from the European Medicines Agency.
authors.affiliation: European Medicines Agency, 30 Churchill Place, Canary Wharf, London E14 5EU, UK.
authors.forename: Matthias P
authors.initials: MP
authors.lastname: Hofer
authors.affiliation: European Medicines Agency, 30 Churchill Place, Canary Wharf, London E14 5EU, UK.
authors.forename: Christina
authors.initials: C
authors.lastname: Jakobsson
authors.affiliation: European Medicines Agency, 30 Churchill Place, Canary Wharf, London E14 5EU, UK.
authors.forename: Nikolaos
authors.initials: N
authors.lastname: Zafiropoulos
authors.affiliation: European Medicines Agency, 30 Churchill Place, Canary Wharf, London E14 5EU, UK.
authors.forename: Spiros
authors.initials: S
authors.lastname: Vamvakas
authors.affiliation: European Medicines Agency, 30 Churchill Place, Canary Wharf, London E14 5EU, UK.
authors.forename: Thorsten
authors.initials: T
authors.lastname: Vetter
authors.affiliation: European Medicines Agency, 30 Churchill Place, Canary Wharf, London E14 5EU, UK.
authors.forename: Jan
authors.initials: J
authors.lastname: Regnstrom
authors.affiliation: Medicines and Healthcare Products Regulatory Agency, 151 Buckingham Palace Road, Victoria, London SW1W 9SZ, UK.
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Hemmings
mesh_terms: D017277:Drug Approval / Q000331:legislation & jurisprudence*; D015195:Drug Design; D005060:Europe; D006077:Government Agencies; D006801:Humans; D018570:Risk Assessment / Q000379:methods